A Method for Producing Induced Pluripotent Stem Cell-Derived Cardiomyocytes from Leigh Syndrome Patients for Its...

Area of Science:

• Biomedical research
• Stem cell biology
• Neurogenetics

Background:

• Leigh syndrome (LS) is a severe genetic disorder affecting ATP production, leading to diverse clinical outcomes and early mortality.
• Current understanding of LS pathogenesis and effective treatments remain limited due to disease complexity and varied genetic origins (nuclear vs. mitochondrial DNA mutations).
• There is a critical need for advanced models to study LS mechanisms and facilitate patient-specific drug discovery.

Purpose of the Study:

• To establish a patient-specific cellular model for Leigh syndrome using induced pluripotent stem cells (iPSCs).
• To differentiate iPSCs from LS patients into cardiomyocytes (iPSC-CMs) for disease modeling and drug validation.
• To evaluate the potential of iPSC-CMs in assessing cellular electrophysiology and disease phenotypes.

Main Methods:

• Generation of iPSCs from Leigh syndrome patient samples.
• Differentiation of patient-derived iPSCs into cardiomyocytes (iPSC-CMs).
• Assessment of iPSC-CM electrophysiological properties using multi-electrode array (MEA) analysis.

Main Results:

• Successful generation and differentiation of iPSCs from LS patients into functional iPSC-CMs.
• MEA analysis demonstrated distinct field potentials in iPSC-CMs, indicating their utility for disease modeling.
• The study highlights the potential of hiPSC-CMs for evaluating drug efficacy and understanding LS pathophysiology.

Conclusions:

• Patient-derived iPSC-CMs represent a powerful tool for studying Leigh syndrome and related disorders.
• This approach facilitates personalized drug screening and development for rare genetic diseases.
• The findings pave the way for novel, patient-centric therapeutic strategies for Leigh syndrome.